Profound Medical Corp PROF 深 沪
等待开盘 02-07 09:30:00 美东时间
6.49
+0.170
+2.69%
华盛通- 最 高6.83
- 今 开6.35
- 成交量 9.72万股
- 最 低 6.31
- 昨 收 6.32
- 总市值 2.36亿
- 52周最高 8.95
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 3.76
- 委 比 92.79%
- 总股本 3629.30万
- 历史最高 28.97
- 量 比 0.38
- 振 幅 8.23%
- 历史最低 3.10
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Profound Medical Marks 500th Sonalleve Procedure Milestone
An announcement from Profound Medical ( ($TSE:PRN) ) is now available. On Febru...
02-05 21:41
Profound Medical Announces Upcoming Investor Events
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will participate in two investor events in February: the Lake Street Life-Sciences Invitational on Feb 4-5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb 10-11 in Snowbird, UT. The events will include one-on-one meetings but no webcasts. Profound develops AI-powered, MRI-guided, incision-free therapies for tissue ablation, commerc...
01-27 21:30
Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual functionThe Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for
01-15 20:42
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Mount Sinai Hospital, ranked No. 6 nationally for Urology, has successfully treated its first prostate cancer patient using the AI-powered, MRI-guided TULSA-PRO system. The TULSA Procedure, an incision-free therapy, uses real-time MRI thermography to precisely heat prostate tissue while preserving continence and sexual function. Mount Sinai is the first health system in the New York Metro Area to offer this innovative treatment, marking a signifi...
01-15 12:30
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Profound Medical Corp. reported that its TULSA-PRO installed base reached 78 systems as of December 31, 2025, surpassing its target of 75 installations. Additionally, the company's qualified sales pipeline grew to 97 new systems. CEO Arun Menawat highlighted expectations for increased patient treatment rates and high-margin recurring revenue growth, driven by the TULSA Procedure's ability to treat a wide range of prostate conditions while preserv...
01-12 13:00
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12
Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raises the price target from $11 to $12.
01-08 03:02
Profound Medical Announces First Non‑Trial Prostate Cancer Patient Treated With TULSA‑PRO At Johns Hopkins
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of
01-06 21:00
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical Corp. has reached a significant milestone by launching its advanced TULSA-PRO system at Johns Hopkins Hospital, treating the first non-clinical-trial prostate cancer patient. The TULSA-PRO system, which combines real-time MRI, AI-enhanced planning, and robotically-driven ultrasound, offers a minimally invasive, precision therapy for prostate cancer and BPH. The procedure is fast, requires no incisions or radiation, and allows pat...
01-06 12:45
Profound Medical Corp. Announces Closing of Private Placement
Profound Medical Corp. completed a private placement of 921,428 common shares to Canadian investors at US$7.00 per share, raising approximately US$6.45 million. The company aims to use the proceeds for expanding sales and marketing, working capital, R&D, strategic transactions, and general corporate purposes. The shares are subject to a 4-month lock-up period and not registered in the U.S., with plans to file a registration statement within four ...
2025-12-30 21:30
